CTRI/2023/09/057663尚未招募3 期
Efficacy and Safety of Imeglimin versus Vildagliptin as add on therapy to Metformin plus Glimepiride in patients of type 2 diabetes mellitus: A Randomized Controlled Trial - NI
Dr Noor Husain0 个研究点目标入组 0 人开始时间: 待定最近更新:
试验速览
- 阶段
- 3 期
- 状态
- 尚未招募
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •1) Diabetes mellitus with HbA1c between 7.5% to 9%, patients already on Metformin more than 100mg daily along with Glimepiride 1 to 2 mg daily.
排除标准
- •1) Type 1 Diabetes mellitus, cardiovascular disease, renal failure,abnormal liver function test or hepatic disease.
- •2) more than 2 hypoglycemic drugs, within 12 weeks has received Imeglimin or Vildagliptin
- •3) Diabetic retinopathy, pancreatitis
- •4) Pregnant and lactating women, known contraindication, hypersensitivity or allergies.
研究者
相似试验
尚未招募
4 期
Comparing the efficacy and safety of imeglimin versus sitagliptin as add-ons to metformin in patients not acheiving glycemic control on metformin.CTRI/2024/03/063813Dr. Kriti Kalra
尚未招募
3 期
A Clinical Trial To Compare The Efficacy And Safety Of Imeglimin ( A Novel Anti-Diabetic agent) With Existing Anti-Diabetic Agents In Newly Diagnosed Type 2 Diabetes Patients.CTRI/2023/11/060291Government Medical College, Jammu
尚未招募
4 期
A study to evaluate the therapeutic effect of Imeglimin by comparing with existing therapy for Type 2 Diabetes MellitusCTRI/2023/11/060206Dr Raj Kamal
已完成
不适用
Comparison of Remogliflozin with vildagliptin in the treatment of diabetesCTRI/2020/02/023120Maulana azad medical college
未知
3 期
To Compare the Efficacy and Safey of Vildagliptin Compared to Voglibose in Patients With Type 2 DiabetesType 2 DiabetesJPRN-jRCT2080220294ovartis Pharma K.K.370